Volume | 5,789 |
|
|||||
News | - | ||||||
Day High | 0.74 | Low High |
|||||
Day Low | 0.71 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Forte Biosciences Inc | FBRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.7158 | 0.71 | 0.74 | 0.7163 | 0.739 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
51 | 5,789 | $ 0.7210053 | $ 4,174 | - | 0.38 - 1.1497 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:57:44 | 6 | $ 0.75 | USD |
Forte Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
45.78M | 36.34M | - | 0 | -31.48M | -0.87 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Forte Biosciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FBRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.78 | 0.78 | 0.71 | 0.7255577 | 9,254 | -0.0637 | -8.17% |
1 Month | 0.682 | 0.78 | 0.62 | 0.7248245 | 25,215 | 0.0343 | 5.03% |
3 Months | 0.5938 | 0.78 | 0.44 | 0.6739011 | 35,542 | 0.1225 | 20.63% |
6 Months | 0.484 | 0.85 | 0.38 | 0.6341155 | 37,147 | 0.2323 | 48.00% |
1 Year | 1.05 | 1.1497 | 0.38 | 0.8148895 | 47,516 | -0.3337 | -31.78% |
3 Years | 34.24 | 43.57 | 0.38 | 6.54 | 309,299 | -33.52 | -97.91% |
5 Years | 17.00 | 53.99 | 0.38 | 8.97 | 264,753 | -16.28 | -95.79% |
Forte Biosciences Description
Forte Biosciences Inc is a clinical-stage biopharmaceutical company, focused on dermatology. The company is developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric patients with atopic dermatitis. It plans to advance FB-401 into a randomized Phase 2 clinical trial. |